DOGE vs USAID, Crypto Framework, Google's $75B AI Spend, US Sovereign Wealth Fund, GLP-1s

Antonio Gracias argues Google will win the AI race because it has proprietary TPU chips, focuses on ROIC, and has a dominant monopoly cash engine to fund the buildout — making it one of the likely long-term AI infrastructure winners.

“Google will also win because they have their TensorFlow chips. They make some of their own chips. They do focus on ROIC, and they have a great monopoly to kind of fund it all.”▶ Listen · 1:13:48 ⚑

FriedbergBullish✓ right so far

Friedberg views Google's $75B CapEx as a strong positive signal, citing the company's historically superior infrastructure management and ROIC discipline, and argues the math easily supports the investment given Google's operating profit base.

“I would view the $75 billion CapEx actually as a very positive signal for the company. I think that it means that they have a really strong line of sight on how they're going to have full utilization and great return on this.”▶ Listen · 1:15:26 ⚑

ChamathBullish✓ right so far

Chamath argues Google's models are best-in-class and its ad business structurally benefits from AI optimization, making the $75B CapEx more a disclosure problem than a fundamental one — the investment is justified but needs better breakdown.

“Google's models are probably the best of all the models across a broad base of capabilities... The other thing that Google has is a money machine that directly benefits from these AI-driven optimizations on ad targeting.”▶ Listen · 1:10:39 ⚑

Antonio Gracias argues xAI will achieve the highest return on invested capital in AI infrastructure due to its world-leading dense GPU cluster (Colossus), lowest-cost and fastest build, and superior training data.

“XAI will have the highest return on capital, and I also think the best training data, and therefore will win.”▶ Listen · 1:13:42 ⚑

FriedbergBullish✓ right so far

Friedberg highlights large-scale VA data showing GLP-1 agonists dramatically reduce cardiac arrest, liver failure, schizophrenia and other serious conditions beyond weight loss — broadening the addressable market and strengthening Eli Lilly's long-term growth thesis.

“On cardiac arrest, you see a 30% decrease in the probability of having cardiac arrest from the cohort that's on the GLP-1s... they have all these clinical trials going on right now for different indications for the GLP-1 receptor agonists.”▶ Listen · 1:25:50 ⚑